SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of August 12, 2026, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

Article I.
DEFINITIONS

…

Notice of Grant of Stock Options and Option Agreement

Curis, Inc.

ID: 04-3505116

128 Spring Street

Lexington, MA 02421

[[FIRSTNAME]] [[LASTNAME]]							Option Number:	[[GRANTNUMBER]]
[[RESADDR1]]							Plan:	[[STOCKOPTIONPLANNAME]]
[[RESCITY]], [[RESSTATEORPROV]] [[RESPOSTALCODE]]							ID:	[[PARTICIPANTID]]

…

Notice of Grant of Stock Options and Option Agreement

Curis, Inc.

ID: 04-3505116

128 Spring Street

Lexington, MA 02421

[[FIRSTNAME]] [[LASTNAME]]							Option Number:	[[GRANTNUMBER]]
[[RESADDR1]]							Plan:	[[STOCKOPTIONPLANNAME]]
[[RESCITY]], [[RESSTATEORPROV]] [[RESPOSTALCODE]]							ID:	[[PARTICIPANTID]]

…

A.G.P./Alliance Global Partners

590 Madison Avenue, 28th Floor

New York, NY 10022

and

Laidlaw & Company (UK) Ltd.

521 5th Ave, 12th Floor

New York, NY 10175

August 12, 2026

Curis, Inc.

128 Spring Street, Building C – Suite 500

Lexington, MA 02421

Attention: Diantha Duvall, Chief Financial Officer

Re:					Placement Agency Agreement

Dear Ms. Duvall:

…

AMENDMENT #1

THIS AMENDMENT #1 (the “Amendment”) to the Transaction Documents (as defined below) is entered into as of June 18, 2026 (the “Effective Date”), by and between IGC Pharma, Inc., a Maryland corporation (the “Company”), and FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “Holder”) (collectively the “Parties”).

BACKGROUND

A. The Company and Holder are the parties to that certain securities purchase agreement dated on April 10, 2026 (the “Purchase Agreement”), pursuant to which the Company issued to Holder that certain promissory note in the original principal amount of $346,910.00 (the “Note”, and collectively with the Purchase Agreement and ancillary documentation entered into between the Parties in connection therewith, the “Transaction Documents”).

B. The Parties desire to amend the Transaction Documents as set forth expressly below.

…

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

Exhibit 10.4

LICENSE AGREEMENT

by and between

ASCENDANT HEALTH SCIENCES LIMITED

and

CUE BIOPHARMA, INC.

dated as of April 30, 2026

LICENSE AGREEMENT

This License Agreement(this “Agreement”) is entered into as of April 30, 2026 (the “Effective Date”) by and between Ascendant Health Sciences Limited, a company incorporated under the laws of the Cayman Islands with an address of Palm Grove Unit 4, 265 Smith Road, George Town, Grand Cayman KY1-9006, Cayman Islands (“Ascendant”), and Cue Biopharma, Inc., a company incorporated in Delaware with an address of 40 Guest Street, Boston, Massachusetts 02135, United States (“Cue”). Ascendant and Cue are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.

Recitals

…

SEPARATION AND RELEASE OF CLAIMS AGREEMENT

This Separation and Release of Claims Agreement (the “Agreement”) is entered into by and between Cue Biopharma, Inc. (the “Company”) and Lucinda Warren (“Executive”) (together, the “Parties”).

WHEREAS, the Company and Executive are parties to that certain Amended and Restated Executive Employment Agreement effective as of March 27, 2026 (the “Employment Agreement”), pursuant to which Executive serves as the Company’s Interim President and Chief Executive Officer and Chief Financial & Business Officer;

WHEREAS, Executive’s last day of employment with the Company will be May 4, 2026 (the “Separation Date”);

WHEREAS, the Parties wish to establish mutually agreeable terms for Executive’s separation from the Company; and

WHEREAS, the Parties agree that the benefits and rights set forth in this Agreement shall be the exclusive benefits and rights due Executive.

…

CUE BIOPHARMA, INC.

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the “Agreement”) is made by and between Cue Biopharma, Inc., a Delaware corporation (“Cue” or the “Company”), and Shao-Lee Lin (“Executive,” and together with Cue, the “Parties”).

WHEREAS, the Company and Executive desire to enter into this Agreement to set forth the conditions under which Executive will be employed by the Company.

NOW, THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1.

POSITION AND DUTIES.

(a)

As of the Effective Date (as defined below), Cue shall employ Executive as its President and CEO. Executive shall have such duties and authority commensurate with the position of President and CEO, and such other duties commensurate with her position that may be assigned by the Board of Directors of Cue (the “Board”).

(b)

…

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

Exhibit 10.7

FIRST AMENDMENT

to the

LICENSE AGREEMENT

This First Amendment to the License Agreement(this “Amendment”) is entered into as of August 14, 2026 (the “Amendment Date”) by and between Ascendant Health Sciences Limited, a company incorporated under the laws of the Cayman Islands with an address of Palm Grove Unit 4, 265 Smith Road, George Town, Grand Cayman KY1-9006, Cayman Islands (“Ascendant”), and Cue Biopharma, Inc., a company incorporated in Delaware with an address of 40 Guest Street, Boston, Massachusetts 02135, United States (“Cue”). Ascendant and Cue are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.

RECITALS:

WHEREAS, Cue and Ascendant are Parties to that certain License Agreement dated April 30, 2026 (the “Original Agreement” and together with this Amendment, the “Agreement”).

…

SECRETARY’S CERTIFIED EXTRACT FROM BOARD MINUTES

AND WRITTEN DESCRIPTION OF SUBSEQUENT MODIFICATION

TO SHARE COMPENSATION ARRANGEMENT

The undersigned, being the duly elected and acting Secretary of ESG Inc., a Nevada corporation (the “Company”), hereby certifies as follows:

1. October 17, 2024 Share Compensation Arrangement

The following is a true and correct extract of the action taken by the Board of Directors of the Company at a duly called meeting held on October 17, 2024, as reflected in the official minutes of the Company:

Upon motion duly made, seconded and unanimously carried, the Board of Directors approved annual stock-based compensation as follows:

	1)	John Wallace, as Chairman of the Board — shares of the Company’s common stock valued at $50,000 annually;

…